BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38003016)

  • 21. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II.
    Ferguson PJ; Currie C; Vincent MD
    Drug Metab Dispos; 1999 Dec; 27(12):1399-405. PubMed ID: 10570020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between platinum drug resistance and epithelial-mesenchymal transition.
    Brozovic A
    Arch Toxicol; 2017 Feb; 91(2):605-619. PubMed ID: 28032148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma-mass spectrometory.
    Kato R; Sato T; Iwamoto A; Yamazaki T; Nakashiro S; Yoshikai S; Fujimoto A; Imano H; Ijiri Y; Mino Y; Chikuma M; Tanaka K; Hayashi T
    Biopharm Drug Dispos; 2019 Jul; 40(7):242-249. PubMed ID: 31219617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin and platinum drugs at the molecular level. (Review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
    Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
    Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
    Pang SK; So WK; Ho YP; Au-Yeung CF
    Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.
    Poulain L; Sichel F; Crouet H; Bureau F; Gauduchon P; Gignoux M; Le Talaër JY
    Cancer Chemother Pharmacol; 1997; 40(5):385-90. PubMed ID: 9272114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs.
    Román DA; Pizarro I; Rivera L; Torres C; Avila J; Cortés P; Gill M
    BMC Res Notes; 2012 Apr; 5():207. PubMed ID: 22546077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.
    Ziliak D; Gamazon ER; Lacroix B; Kyung Im H; Wen Y; Huang RS
    Mol Cancer Ther; 2012 Sep; 11(9):2054-61. PubMed ID: 22752226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relations between approved platinum drugs and non-coding RNAs in mesothelioma.
    Biersack B
    Noncoding RNA Res; 2018 Dec; 3(4):161-173. PubMed ID: 30809599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma.
    Hastings JF; Gonzalez Rajal A; Latham SL; Han JZ; McCloy RA; O'Donnell YE; Phimmachanh M; Murphy AD; Nagrial A; Daneshvar D; Chin V; Watkins DN; Burgess A; Croucher DR
    Elife; 2020 Jun; 9():. PubMed ID: 32513387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics.
    Schoch S; Gajewski S; Rothfuß J; Hartwig A; Köberle B
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32967255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
    Riquelme E; Suraokar M; Behrens C; Lin HY; Girard L; Nilsson MB; Simon G; Wang J; Coombes KR; Lee JJ; Hong WK; Heymach J; Minna JD; Wistuba II
    Clin Cancer Res; 2014 Jul; 20(14):3849-61. PubMed ID: 24850841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
    Stordal B; Pavlakis N; Davey R
    Cancer Treat Rev; 2007 Jun; 33(4):347-57. PubMed ID: 17383100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of cytotoxicities of platinum compounds.
    Goodisman J; Hagrman D; Tacka KA; Souid AK
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
    Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
    PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization.
    Mlynska A; Povilaityte E; Zemleckaite I; Zilionyte K; Strioga M; Krasko J; Dobrovolskiene N; Peng MW; Intaite B; Pasukoniene V
    Am J Reprod Immunol; 2018 Sep; 80(3):e12996. PubMed ID: 29904979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of New Regulators of Pancreatic Cancer Cell Sensitivity to Oxaliplatin and Cisplatin.
    Skripova V; Vlasenkova R; Zhou Y; Astsaturov I; Kiyamova R
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
    Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
    Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.